Annual Current Liabilities
$206.00 K
+$19.00 K+10.16%
December 31, 2023
Summary
- As of February 6, 2025, XTLB annual total current liabilities is $206.00 thousand, with the most recent change of +$19.00 thousand (+10.16%) on December 31, 2023.
- During the last 3 years, XTLB annual current liabilities has fallen by -$48.00 thousand (-18.90%).
- XTLB annual current liabilities is now -96.16% below its all-time high of $5.37 million, reached on December 31, 2007.
Performance
XTLB Current Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Current Liabilities
$2.47 M
+$2.30 M+1395.15%
September 30, 2024
Summary
- As of February 6, 2025, XTLB quarterly total current liabilities is $2.47 million, with the most recent change of +$2.30 million (+1395.15%) on September 30, 2024.
- Over the past year, XTLB quarterly current liabilities has increased by +$2.24 million (+1006.28%).
- XTLB quarterly current liabilities is now -61.96% below its all-time high of $6.49 million, reached on June 30, 2008.
Performance
XTLB Quarterly Current Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Current Liabilities Formula
Current Liabilities = Accounts Payable + Short-Term Debt + Accrued Expenses + Other Current Liabilities
XTLB Current Liabilities Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +10.2% | +1006.3% |
| 3 y3 years | -18.9% | +1006.3% |
| 5 y5 years | -18.6% | +1255.5% |
XTLB Current Liabilities Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -10.8% | +10.2% | at high | +1512.4% |
| 5 y | 5-year | -18.9% | +10.2% | at high | +1512.4% |
| alltime | all time | -96.2% | +10.2% | -62.0% | +1512.4% |
XTL Biopharmaceuticals Current Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $2.47 M(+1395.2%) |
| Jun 2024 | - | $165.00 K(-26.0%) |
| Mar 2024 | - | $223.00 K(+8.3%) |
| Dec 2023 | $206.00 K(+10.2%) | $206.00 K(+27.2%) |
| Sep 2023 | - | $162.00 K(-0.6%) |
| Jun 2023 | - | $163.00 K(-32.4%) |
| Mar 2023 | - | $241.00 K(+28.9%) |
| Dec 2022 | $187.00 K(-19.0%) | $187.00 K(+22.2%) |
| Sep 2022 | - | $153.00 K(-11.0%) |
| Jun 2022 | - | $172.00 K(-33.8%) |
| Mar 2022 | - | $260.00 K(+12.6%) |
| Dec 2021 | $231.00 K(-9.1%) | $231.00 K(+24.9%) |
| Sep 2021 | - | $185.00 K(-28.3%) |
| Jun 2021 | - | $258.00 K(+2.8%) |
| Mar 2021 | - | $251.00 K(-1.2%) |
| Dec 2020 | $254.00 K(+9.5%) | $254.00 K(+39.6%) |
| Sep 2020 | - | $182.00 K(-6.2%) |
| Jun 2020 | - | $194.00 K(-20.5%) |
| Mar 2020 | - | $244.00 K(+5.2%) |
| Dec 2019 | $232.00 K(-8.3%) | $232.00 K(+16.0%) |
| Sep 2019 | - | $200.00 K(-1.5%) |
| Jun 2019 | - | $203.00 K(-14.0%) |
| Mar 2019 | - | $236.00 K(-6.7%) |
| Dec 2018 | $253.00 K(-15.7%) | $253.00 K(+28.4%) |
| Sep 2018 | - | $197.00 K(-0.5%) |
| Jun 2018 | - | $198.00 K(-14.7%) |
| Mar 2018 | - | $232.00 K(-22.7%) |
| Dec 2017 | $300.00 K(-9.1%) | $300.00 K(+4.9%) |
| Sep 2017 | - | $286.00 K(-25.1%) |
| Jun 2017 | - | $382.00 K(-29.8%) |
| Mar 2017 | - | $544.00 K(+64.8%) |
| Dec 2016 | $330.00 K | $330.00 K(+27.9%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2016 | - | $258.00 K(-40.8%) |
| Dec 2015 | $436.00 K(-54.8%) | $436.00 K(+66.4%) |
| Sep 2015 | - | $262.00 K(+13.4%) |
| Jun 2015 | - | $231.00 K(-76.1%) |
| Dec 2014 | $965.00 K(-20.8%) | $965.00 K(-18.5%) |
| Sep 2014 | - | $1.18 M(-12.2%) |
| Jun 2014 | - | $1.35 M(+3.3%) |
| Mar 2014 | - | $1.30 M(+7.1%) |
| Dec 2013 | $1.22 M(-26.1%) | $1.22 M(-5.4%) |
| Sep 2013 | - | $1.29 M(-5.8%) |
| Jun 2013 | - | $1.37 M(-13.4%) |
| Mar 2013 | - | $1.58 M(-4.1%) |
| Dec 2012 | $1.65 M(-69.3%) | $1.65 M(+123.4%) |
| Sep 2012 | - | $738.00 K(-11.3%) |
| Jun 2012 | - | $832.00 K(-16.9%) |
| Mar 2012 | - | $1.00 M(+55.7%) |
| Sep 2011 | - | $643.00 K(-7.9%) |
| Jun 2011 | - | $698.00 K(-15.4%) |
| Mar 2011 | - | $825.00 K(-7.0%) |
| Sep 2010 | - | $887.00 K(+0.6%) |
| Jun 2010 | - | $882.00 K(+20.3%) |
| Mar 2010 | - | $733.00 K(+15.8%) |
| Sep 2009 | - | $633.00 K(-90.2%) |
| Jun 2008 | - | $6.49 M(+20.8%) |
| Dec 2007 | $5.37 M(+57.8%) | $5.37 M(+31.1%) |
| Jun 2007 | - | $4.09 M(+20.3%) |
| Dec 2006 | $3.40 M(+41.4%) | $3.40 M(+9.6%) |
| Jun 2006 | - | $3.10 M(+29.0%) |
| Dec 2005 | $2.41 M(-31.9%) | $2.41 M(-21.9%) |
| Jun 2005 | - | $3.08 M(-12.9%) |
| Dec 2004 | $3.53 M(+17.7%) | $3.53 M(-9.5%) |
| Jun 2004 | - | $3.90 M |
| Dec 2003 | $3.00 M | - |
FAQ
- What is XTL Biopharmaceuticals annual total current liabilities?
- What is the all time high annual current liabilities for XTL Biopharmaceuticals?
- What is XTL Biopharmaceuticals annual current liabilities year-on-year change?
- What is XTL Biopharmaceuticals quarterly total current liabilities?
- What is the all time high quarterly current liabilities for XTL Biopharmaceuticals?
- What is XTL Biopharmaceuticals quarterly current liabilities year-on-year change?
What is XTL Biopharmaceuticals annual total current liabilities?
The current annual current liabilities of XTLB is $206.00 K
What is the all time high annual current liabilities for XTL Biopharmaceuticals?
XTL Biopharmaceuticals all-time high annual total current liabilities is $5.37 M
What is XTL Biopharmaceuticals annual current liabilities year-on-year change?
Over the past year, XTLB annual total current liabilities has changed by +$19.00 K (+10.16%)
What is XTL Biopharmaceuticals quarterly total current liabilities?
The current quarterly current liabilities of XTLB is $2.47 M
What is the all time high quarterly current liabilities for XTL Biopharmaceuticals?
XTL Biopharmaceuticals all-time high quarterly total current liabilities is $6.49 M
What is XTL Biopharmaceuticals quarterly current liabilities year-on-year change?
Over the past year, XTLB quarterly total current liabilities has changed by +$2.24 M (+1006.28%)